Magdalena Krakowska

Dr. Magdalena Krakowska

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MGMagdalena Grabiec
Magdalena Grabiec
DRDominika Raźniewska
Dominika Raźniewska
TKTadeusz Kałużewski
Tadeusz Kałużewski
MKMagdalena Krakowska
Magdalena Krakowska
BRBarbara Radecka
Barbara Radecka
PPPiotr Potemski
Piotr Potemski
Objectives: Colorectal cancer is a major public health concern, ranking third in incidence among all malignant tumors both in Poland and globally. We conducted a retrospective study to evaluate the effectiveness of regorafenib in patients with metastatic colorectal cancer ineligible for local therapy treated at two Polish comprehensive cancer centers between 2021 and 2024. Methods: The analysis included 29 patients who had previously received all standard therapies: fluoropyrimidines, oxaliplatin, and irinotecan (in a multi-agent regimen or sequentially) and bevacizumab (anti-VEGF therapy). In patients with tumors negative for KRAS, NRAS and BRAF mutations, cetuximab or panitumumab (anti-EGFR therapy) were also used. Results: The median progression-free survival (PFS) was 2.5 months, and the median overall survival (OS) was 5.8 months. Disease stabilization was observed in five patients, with a median duration of 5.6 months, and no partial or complete remission were recorded. Conclusions: Our results were similar to those of the phase III CORRECT trial, which established the clinical utility of regorafenib. Only minor differences in survival outcomes were noted—likely due to real-world variability in patient characteristics and timing of treatment assessments. However, continued investigation of personalized and sequential treatment strategies that contain anti-angiogenic drugs is warranted to optimize outcomes.